Esperion Therapeutics, Inc. News Releases https://investor.esperion.com/ Esperion Therapeutics, Inc. News Releases en Esperion to Participate in Upcoming Investor Conferences https://investor.esperion.com/news-releases/news-release-details/esperion-participate-upcoming-investor-conferences-1 ANN ARBOR, Mich., May 10, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences: Bank of America Merrill Lynch Healthcare Conference 2019 in Las Vegas on Tuesday, May 14, 2019 at Fri, 10 May 2019 07:59:49 -0400 Esperion Therapeutics, Inc. News Releases 10681 Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results https://investor.esperion.com/news-releases/news-release-details/esperion-provides-bempedoic-acid-franchise-development-program-6 ANN ARBOR, Mich., May 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the first quarter ended March 31, 2019. “The potential of bempedoic acid is being broadly realized as evidenced by publication and Wed, 08 May 2019 07:00:00 -0400 Esperion Therapeutics, Inc. News Releases 10661 Esperion to Host Analyst and Investor Day Event on June 13 https://investor.esperion.com/news-releases/news-release-details/esperion-host-analyst-and-investor-day-event-june-13 ANN ARBOR, Mich., May 07, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00 a.m. Eastern Time. The event will feature presentations from members of the Esperion Lipid Management Team as Tue, 07 May 2019 05:30:46 -0400 Esperion Therapeutics, Inc. News Releases 10651 Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review https://investor.esperion.com/news-releases/news-release-details/esperion-announces-us-fda-acceptance-new-drug-applications-ndas – Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver – – February 21, 2020 PDUFA Target Date Goal for Bempedoic Acid and February 26, 2020 PDUFA Target Date Goal for the Bempedoic Acid / Ezetimibe Combination Tablet Sun, 05 May 2019 17:00:14 -0400 Esperion Therapeutics, Inc. News Releases 10631 Esperion to Present at the Needham & Company 18th Annual Healthcare Conference https://investor.esperion.com/news-releases/news-release-details/esperion-present-needham-company-18th-annual-healthcare ANN ARBOR, Mich., April 02, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol Tue, 02 Apr 2019 16:30:09 -0400 Esperion Therapeutics, Inc. News Releases 10596 Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results https://investor.esperion.com/news-releases/news-release-details/esperion-announces-publication-journal-american-heart  –  Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant – –  Over 24-Weeks, Bempedoic Acid Was Observed to be Safe, Well-Tolerated, and the Muscle-Related Adverse Event Rate Did Not Differ from Placebo – –  Bempedoic Mon, 01 Apr 2019 16:15:15 -0400 Esperion Therapeutics, Inc. News Releases 10581 Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions https://investor.esperion.com/news-releases/news-release-details/esperion-announces-late-breaking-presentation-final-results –Study 2 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP– –Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Adverse Event Profile was Similar to that of Placebo– –Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor Mon, 18 Mar 2019 09:20:09 -0400 Esperion Therapeutics, Inc. News Releases 10551 Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine https://investor.esperion.com/news-releases/news-release-details/esperion-announces-publication-bempedoic-acid-study-1-results –  Study 1 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – –  Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Did Not Lead to Higher Overall Adverse Events Compared With Placebo – –  Bempedoic Acid is an Oral, Once-daily ATP Citrate Wed, 13 Mar 2019 17:05:09 -0400 Esperion Therapeutics, Inc. News Releases 10526 Esperion to Participate in Upcoming Investor Conferences https://investor.esperion.com/news-releases/news-release-details/esperion-participate-upcoming-investor-conferences-0 ANN ARBOR, Mich., March 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol Mon, 04 Mar 2019 16:30:10 -0500 Esperion Therapeutics, Inc. News Releases 10511 Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions https://investor.esperion.com/news-releases/news-release-details/esperion-announces-presentation-bempedoic-acid-pivotal-phase-3 ANN ARBOR, Mich., March 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the results from Study 2 (1002-047, also known as CLEAR Wisdom, a pivotal Phase 3 study) of bempedoic acid will be presented in a late-breaking clinical trial session at the American College of Mon, 04 Mar 2019 08:00:51 -0500 Esperion Therapeutics, Inc. News Releases 10501